181 related articles for article (PubMed ID: 11006034)
1. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells.
Huang M; Page C; Reynolds RK; Lin J
Gynecol Oncol; 2000 Oct; 79(1):67-73. PubMed ID: 11006034
[TBL] [Abstract][Full Text] [Related]
2. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
Nishimoto A; Yu Y; Lu Z; Mao X; Ren Z; Watowich SS; Mills GB; Liao WS; Chen X; Bast RC; Luo RZ
Cancer Res; 2005 Aug; 65(15):6701-10. PubMed ID: 16061651
[TBL] [Abstract][Full Text] [Related]
3. [Relationship of Stat3 and its target gene products with malignancy in human colorectal carcinoma].
Ma XT; Wang S; Ye YJ; Du RY; Cui ZR
Ai Zheng; 2003 Nov; 22(11):1135-9. PubMed ID: 14613639
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of potential Stat3-regulated genes in human breast cancer.
Hsieh FC; Cheng G; Lin J
Biochem Biophys Res Commun; 2005 Sep; 335(2):292-9. PubMed ID: 16081048
[TBL] [Abstract][Full Text] [Related]
5. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma.
Masuda M; Suzui M; Yasumatu R; Nakashima T; Kuratomi Y; Azuma K; Tomita K; Komiyama S; Weinstein IB
Cancer Res; 2002 Jun; 62(12):3351-5. PubMed ID: 12067972
[TBL] [Abstract][Full Text] [Related]
6. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
Rosen DG; Mercado-Uribe I; Yang G; Bast RC; Amin HM; Lai R; Liu J
Cancer; 2006 Dec; 107(11):2730-40. PubMed ID: 17063503
[TBL] [Abstract][Full Text] [Related]
7. STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells.
de Groot RP; Raaijmakers JA; Lammers JW; Koenderman L
Mol Cell Biol Res Commun; 2000 May; 3(5):299-305. PubMed ID: 10964754
[TBL] [Abstract][Full Text] [Related]
8. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo.
Kijima T; Niwa H; Steinman RA; Drenning SD; Gooding WE; Wentzel AL; Xi S; Grandis JR
Cell Growth Differ; 2002 Aug; 13(8):355-62. PubMed ID: 12193474
[TBL] [Abstract][Full Text] [Related]
9. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
Buettner R; Mora LB; Jove R
Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
[TBL] [Abstract][Full Text] [Related]
10. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas.
Savarese TM; Campbell CL; McQuain C; Mitchell K; Guardiani R; Quesenberry PJ; Nelson BE
Cytokine; 2002 Mar; 17(6):324-34. PubMed ID: 12061840
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.
Leslie K; Lang C; Devgan G; Azare J; Berishaj M; Gerald W; Kim YB; Paz K; Darnell JE; Albanese C; Sakamaki T; Pestell R; Bromberg J
Cancer Res; 2006 Mar; 66(5):2544-52. PubMed ID: 16510571
[TBL] [Abstract][Full Text] [Related]
12. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.
Quintanilla-Martinez L; Kremer M; Specht K; Calzada-Wack J; Nathrath M; Schaich R; Höfler H; Fend F
Am J Pathol; 2003 May; 162(5):1449-61. PubMed ID: 12707028
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors.
Karni R; Jove R; Levitzki A
Oncogene; 1999 Aug; 18(33):4654-62. PubMed ID: 10467412
[TBL] [Abstract][Full Text] [Related]
14. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.
Xi S; Gooding WE; Grandis JR
Oncogene; 2005 Feb; 24(6):970-9. PubMed ID: 15592503
[TBL] [Abstract][Full Text] [Related]
15. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L).
Frankel A; Rosen K; Filmus J; Kerbel RS
Cancer Res; 2001 Jun; 61(12):4837-41. PubMed ID: 11406560
[TBL] [Abstract][Full Text] [Related]
16. Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells.
Lin J; Jin X; Rothman K; Lin HJ; Tang H; Burke W
Cancer Res; 2002 Jan; 62(2):376-80. PubMed ID: 11809683
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2.
Rahaman SO; Vogelbaum MA; Haque SJ
Cancer Res; 2005 Apr; 65(7):2956-63. PubMed ID: 15805299
[TBL] [Abstract][Full Text] [Related]
18. Oncostatin M activates stat DNA binding and transcriptional activity in primary human fetal astrocytes: low- and high-passage cells have distinct patterns of stat activation.
Schaefer LK; Wang S; Schaefer TS
Cytokine; 2000 Nov; 12(11):1647-55. PubMed ID: 11052815
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
20. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
